Released Aug 6, 2021, before the open
10-Q filed Aug 6, 2021, 37 days after period end · 0001564590-21-041921
Q2 2021 · 10-Q
Revenue$121.39M$121.39M +66.0% vs Q2 2020+15.0% vs Q1 2021
Net Income$2.42M$2.42M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted$0.12$0.12 N/M vs Q2 2020N/M vs Q1 2021
Gross Profit$93,955,000+88.0%
Operating Income$4,267,000N/M
Operating Cash Flowderived-$2,177,000N/M
Free Cash Flowderived-$6,847,000N/M
Margins · derived
Gross margin77.4%+9.1 pt vs Q2 2020
Operating margin3.5%+32.2 pt vs Q2 2020
Net margin2.0%+27.2 pt vs Q2 2020
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $121.39M | $73.14M | $115.85M | $111.55M |
| Net Income | $2.42M | -$18.42M | -$547.00K | $925.00K |
| EPS Diluted | $0.12 | -$0.96 | -$0.03 | $0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR